BGM
MLYS icon

Burkehill Global Management’s Mineralys Therapeutics MLYS Stock Holding History

Burkehill Global Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.06M Hold
150,000
– – 0.2% 86
2025
Q4 		$5.44M Hold
150,000
– – 0.36% 74
2025
Q3 		$5.69M Buy
+150,000
New +$3.24M 0.32% 79

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Burkehill Global Management's MLYS Position: Q1 2026 in Review

Burkehill Global Management held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 150,000 shares worth $4.06M. The position accounts for 0.2% of the portfolio, ranked #86.

Burkehill Global Management first reported a position in MLYS in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.69M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Burkehill Global Management held 150,000 shares of Mineralys Therapeutics worth $4.06M as of Q1 2026.
  • Burkehill Global Management left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up 0.2% of Burkehill Global Management's portfolio in Q1 2026, its #86 holding.
  • Burkehill Global Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Burkehill Global Management's Mineralys Therapeutics position peaked at $5.69M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.